JP2017509351A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509351A5
JP2017509351A5 JP2016561993A JP2016561993A JP2017509351A5 JP 2017509351 A5 JP2017509351 A5 JP 2017509351A5 JP 2016561993 A JP2016561993 A JP 2016561993A JP 2016561993 A JP2016561993 A JP 2016561993A JP 2017509351 A5 JP2017509351 A5 JP 2017509351A5
Authority
JP
Japan
Prior art keywords
genes
biological sample
patient
probes
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016561993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072610 external-priority patent/WO2015103166A1/en
Publication of JP2017509351A publication Critical patent/JP2017509351A/ja
Publication of JP2017509351A5 publication Critical patent/JP2017509351A5/ja
Pending legal-status Critical Current

Links

JP2016561993A 2013-12-30 2014-12-29 前立腺癌遺伝子プロファイル及びその使用方法 Pending JP2017509351A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361921739P 2013-12-30 2013-12-30
US61/921,739 2013-12-30
PCT/US2014/072610 WO2015103166A1 (en) 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same

Publications (2)

Publication Number Publication Date
JP2017509351A JP2017509351A (ja) 2017-04-06
JP2017509351A5 true JP2017509351A5 (enExample) 2018-01-25

Family

ID=53493959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561993A Pending JP2017509351A (ja) 2013-12-30 2014-12-29 前立腺癌遺伝子プロファイル及びその使用方法

Country Status (8)

Country Link
US (1) US20160326594A1 (enExample)
EP (1) EP3090265B1 (enExample)
JP (1) JP2017509351A (enExample)
CN (1) CN106796236A (enExample)
AU (1) AU2014373927B2 (enExample)
CA (1) CA2934828A1 (enExample)
WO (1) WO2015103166A1 (enExample)
ZA (1) ZA201604370B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2017127550A1 (en) * 2016-01-19 2017-07-27 Wayne State University Prostate cancer aggressiveness gene signatures for subjects of african or european descent
CA3062573A1 (en) * 2017-05-12 2018-11-15 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
US11530451B2 (en) * 2018-03-02 2022-12-20 The Johns Hopkins University Methods for prostate cancer detection
CN110054674B (zh) * 2019-03-07 2022-08-05 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap2-19及应用
CN110628908B (zh) * 2019-09-19 2022-05-10 北京恩泽康泰生物科技有限公司 用于前列腺癌诊断分级和良恶性预测的生物标志物及检测试剂盒
JP7784997B2 (ja) * 2020-06-18 2025-12-12 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） 前立腺癌の分子分類器
CN111893177B (zh) * 2020-08-19 2022-10-04 南通大学 遗传性耳聋诱导基因的突变筛选方法及突变检测试剂盒
CN113284559B (zh) * 2021-07-21 2021-10-15 暨南大学 一种物种基因组的启动子查询方法、系统及设备
CN120118995A (zh) * 2024-09-25 2025-06-10 深圳汇芯生物医疗科技有限公司 用于检测前列腺癌生物标志物的引物组、探针组、试剂盒及方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20050032065A1 (en) * 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US10066268B2 (en) * 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
EP1824995A2 (en) * 2004-11-24 2007-08-29 St. George's Enterprises Limited Diagnosis of prostate cancer
EP1934603A4 (en) * 2005-09-19 2010-01-06 Univ Johns Hopkins BIOMARKER FOR PROSTATE CANCER
WO2008058018A2 (en) * 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20080254481A1 (en) * 2006-11-13 2008-10-16 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
CA2719172C (en) * 2008-04-10 2020-08-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg8 gene expression and detection and treatment methods based on those alterations
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
FR2945820A1 (fr) * 2009-05-25 2010-11-26 Univ Clermont Auvergne Panel de genes pour le pronostic du cancer de la prostate
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
IL243203A (en) * 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2514836B1 (en) * 2011-04-19 2016-06-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prostate cancer markers
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
EP2751570A4 (en) * 2011-08-31 2015-08-12 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
SE536352C2 (sv) * 2011-10-24 2013-09-03 Chundsell Medicals Ab Markörgener för klassificiering av prostatacancer
ES2616129T3 (es) * 2011-11-04 2017-06-09 Mdxhealth Research B.V. Combinaciones de marcadores moleculares en cáncer de próstata que proporcionan una herramienta para diagnóstico con mejor sensibilidad/especificidad
US9863002B2 (en) * 2012-06-04 2018-01-09 North Carolina Central University Genetic determinants of prostate cancer risk

Similar Documents

Publication Publication Date Title
JP2017509351A5 (enExample)
Feng et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy
DK3013986T3 (en) ASSESSMENT OF PI3K CELL SIGNALING ACTIVITY ACTIVITIES USING MATHEMATICAL MODELING OF TARGET EXPRESSION
Bidard et al. Translating metastasis-related biomarkers to the clinic—progress and pitfalls
JP2014531573A5 (enExample)
Wu et al. MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer
JP2017507320A5 (enExample)
Zhang et al. Deep learning promotes profiling of multiple miRNAs in single extracellular vesicles for cancer diagnosis
JP2013500001A5 (enExample)
JP2013514074A5 (enExample)
ES2603956T3 (es) Método y programa para determinar la sensibilidad a la quimioterapia neoadyuvante para el cáncer de mama
US20160326594A1 (en) Prostate cancer gene profiles and methods of using the same
Tao et al. Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review
Annaratone et al. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization
Verhaegh et al. Knowledge-based computational models
HRP20220128T1 (hr) MARKERI mRNA NA TEMELJU UKUPNE KRVI ZA PREDVIĐANJE RAKA PROSTATE I POSTUPCI ZA OTKRIVANJE ISTOG
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
Caberlotto et al. Systems biology meets-omic technologies: novel approaches to biomarker discovery and companion diagnostic development
JP2016073287A (ja) 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット
RU2011134644A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
Mengual et al. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers
Ding et al. Multimodal Artificial Intelligence‐Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology‐Positive Gastric Cancer
Pedrazzoli Currently debated topics on surgical treatment of pancreatic ductal adenocarcinoma: a narrative review on surgical treatment of borderline resectable, locally advanced, and synchronous or metachronous oligometastatic tumor
IL317236A (en) Predicting peptide receptor radiotherapy using gene expression testing
CN105624271A (zh) 一种与结直肠癌相关的miRNA及其应用